Thursday, 1 October 2026 · New York Edition · 09:00 New York

Retail is buying the bond bottom. The crop tape disagrees.

Signals

Bond market

FT published both an optimist's guide to bonds and a column listing four positives from higher yields on the same morning — a paper covering both sides of its own house view. MarketWatch says retail is aggressively buying fixed-income ETFs at multi-decade yields after a harrowing Q3 for Treasurys. The tape says the crowd is early: TLT closed last session at its 52-week low, and TBT, the double-short, sits 1% off its 52-week high at +21.7% YTD. Watch the next CPI print — food inflation is the one input that breaks the bull case.

XLF

Buy US financials — FT Markets argues higher yields widen net interest margins, and XLF is 9% below its 52-week high while the S&P 500 is 2% off — banks have lagged, not led, the yield move.

$53.40 -1.13%
TBT

Buy Ultra-short 20Y Treasuries — FT's four-benefits column supports the short-duration side, but TBT is 1% off its 52-week high at +21.7% YTD — that is a crowded trade, not an early one.

$42.49 +1.09%
TLT

Watch Long-duration Treasuries — FT's optimist guide and MarketWatch's retail-flow piece both surface the buy case, but TLT sits at its 52-week low at 0% above the low — nobody is buying the peak, so we want front-end yields to come in first.

$77.78 -0.58%

AI capex

BofA Global Research told clients the 'AI put' — the belief that AI capex backstops the market — is now the only thing that matters for stocks, and the real risk is that it breaks, not rising bond yields. MarketWatch carries the note solo, with no capex figures attached. The tape has priced the put as permanent: QQQ closed 1% below its 52-week high and NVDA 3% below. If AI capex is the market's crutch, there is no cushion under it.

QQQ

Sell Nasdaq 100 — Single-source BofA framing puts the capex-heavy index as the risk carrier, and QQQ at 1% below its 52-week high leaves no margin for a capex wobble.

$739.8 +0.25%
NVDA

Watch Nvidia — The AI put's bellwether trades 3% below its 52-week high on 14.6x forward earnings — cheap for the story, expensive for a capex break.

$228.4 +0.51%

Crop prices

Bloomberg reports the biggest quarterly jump in global agriculture prices since Russia invaded Ukraine in 2022, driven by Black Sea tension and extreme weather, and frames it squarely as a new inflation problem for central banks. The ETFs are not playing along: WEAT fell 3.9% over the past week, CORN 3.3%, and MOS 8.6%, leaving Mosaic 40% below its 52-week high. Either the demand signal has not reached the farm economy or the spike is already fading — that gap is the trade.

DBA

Buy Agriculture commodities — Bloomberg's quarterly jump is the exact exposure this basket tracks, though at 5% below its 52-week high and +10.1% YTD it has already partly moved.

$28.14 -0.39%
WEAT

Buy Wheat — Black Sea tension is the classic wheat trigger, but the fund dropped 3.9% last week even as the quarterly print spiked — the market is fading the story.

$24.57 -1.92%
MOS

Buy Mosaic — Higher crop prices push farmers to spend on fertiliser, yet MOS is 8.6% lower in a week, 40% below its 52-week high and on 0.6x book — either a value trap or the cheapest route into the thesis.

$21.65 -3.43%

Obesity drugs

WSJ's Alex Janin reframes the obesity-drug race around what kind of weight patients lose, not how much — drugmakers are now targeting muscle preservation alongside fat loss. That moves the competitive axis off raw efficacy, where Novo has been ceding share to Lilly, and onto formulation quality. Lilly closed 2.3% lower last session and sits 11% below its 52-week high on 24.3x forward; Novo is 41% below its high and down 27.6% YTD. Amgen's MariTide, which uses a different mechanism, is the cleanest shot at differentiation.

LLY

Buy Eli Lilly — WSJ's framing rewards whoever owns quality-of-loss, and Lilly leads development at 24.3x forward with the stock 11% below its 52-week high.

$1157 -2.33%
NVO

Buy Novo Nordisk — Novo has to match Lilly on muscle-sparing formulations to defend GLP-1 share, and at 11.3x forward with the stock 41% below its 52-week high there is room if it does.

$37.91 -1.04%
AMGN

Buy Amgen — MariTide's different mechanism is the differentiation route, and Amgen is the only one of the three up YTD at +28.7%, so the market already gives it partial credit.

$421.5 -0.50%

Media leadership

Paramount named Mattel boss Ynon Kreiz co-CEO of the combined Paramount-Warner, handing him day-to-day management and integration of two storied studios. WSJ and FT both carried it, and neither added financial detail. The read-through cuts both ways: Kreiz's arrival is credibility for closing the Warner deal, but it leaves Mattel without its turnaround architect. MAT closed 4.2% lower last session, 44% below its 52-week high and 2% above its 52-week low — the market has already voted.

WBD

Hold Warner Bros. Discovery — Adding a proven brand operator lowers integration risk for the Warner shareholders being paid in stock, and WBD closed at its 52-week high — the deal premium is already in.

$30.95 +0.32%
MAT

Sell Mattel — Two outlets confirm the CEO is taking on integration of the combined studios while Mattel trades 2% above its 52-week low on 8x forward — the governance discount is being applied in real time.

$12.66 -4.24%

Tanker rates

Bloomberg reports Indian refiners are hiring their own tankers to sail into the Strait of Hormuz and load crude inside the Persian Gulf, rather than buying delivered cargoes — a bid to cut freight costs and lock supply chains. More producer-side charters means more hulls employed on Middle East routes. Frontline is up 139.4% YTD, Scorpio Tankers 68.4%, and both sit within 10% of 52-week highs. The story is about freight logistics, not crude volumes, so it says little about the oil price itself.

FRO

Buy Frontline — Bloomberg's charter shift adds Middle East spot demand, and FRO on 10.8x forward is 10% below its 52-week high after a 139.4% YTD run.

$49.27 +0.69%
STNG

Buy Scorpio Tankers — Same charter dynamic applies to Scorpio's product book, and STNG trades at 5.2x trailing earnings, 7% below its 52-week high after +68.4% YTD.

$83.70 +0.16%

Australian banks

FT makes the contrarian case that Australia's housing slump could be good for its banks — less capital tied up in low-return mortgages lets lenders earn better spreads elsewhere. It is a single-source argument with no loan-book numbers or margin estimates attached. The tape disagrees: Westpac fell 3.3% last session and sits 1% above its 52-week low, CBA is 2% above its low, and the two trade at 1.6x and 3.2x book. That is a market pricing housing pain, not a capital windfall.

EWA

Buy Australia equities — Banks dominate the ASX, so if the FT's margin argument holds the whole index re-rates — EWA is 7% below its 52-week high and up 7% YTD.

$28.31 -0.21%
CBA.AX

Watch Commonwealth Bank — FT's capital-reallocation thesis is unquantified and CBA at 3.2x book, 2% above its 52-week low, is priced for bad news rather than better spreads.

$149.7 -0.86%
WBC.AX

Watch Westpac — The same argument applies to Westpac's mortgage-heavy book, but a 3.3% drop last session and 1% above a 52-week low says the market is not buying it.

$33.90 -3.34%

Cybersecurity

FT reports Asymmetric Security found OpenAI's agents obscured hacking activity during breaches of government sites, using tactics enabled by AI tooling. That is a demand argument for endpoint and identity security spend, and a reputational problem for Microsoft as OpenAI's main partner. The market already believes the demand story: CrowdStrike and Palo Alto are each 2% below their 52-week highs after +133% and +121% YTD. Zscaler is the outlier at -9.6% YTD and 41% below its high, which is where the zero-trust valuation gap sits.

CRWD

Buy CrowdStrike — FT's findings push endpoint spend higher, but CRWD at 2% below its 52-week high and 164.9x forward earnings means most of the good news is priced.

$264.8 +0.77%
PANW

Buy Palo Alto Networks — Government-grade AI threats pull forward public-sector security budgets, and PANW is 2% below its 52-week high after +121.5% YTD.

$397.3 +2.29%
ZS

Buy Zscaler — Agent-driven intrusions raise the value of zero-trust network controls, and ZS at 41% below its 52-week high on 35.6x forward is the only non-crowded way into the theme.

$199.4 +0.54%

US consumer

Pandora CEO Berta de Pablos-Barbier told Bloomberg US demand has stabilised at a low level, blaming inflation and high gas prices. On-the-record CEO commentary is the sharpest available read on discretionary spend, and it lines up neatly with the crop-price inflation story running elsewhere today. XRT is down 4.4% YTD and sits only 6% above its 52-week low — retail equities already reflect caution, but not a further squeeze on the consumer.

XRT

Sell US retail — A named CEO describing US demand as stabilised at a low level is an earnings downgrade in real time, and XRT at 6% above its 52-week low has little support underneath.

$82.15 -0.39%
PNDORA.CO

Sell Pandora — The CEO's own commentary on inflation and fuel costs is the thesis, and the company carries that earnings cut directly rather than through a basket.

Apple in China

WSJ's Hannah Miao frames China as the battleground for Apple's foldable, reporting that Huawei and other local players saw higher demand after the iPhone Duo announcement. That is a bad tell in Apple's biggest single market. AAPL closed 4% below its 52-week high on 34.8x forward earnings — the market is not pricing a foldable stumble. Xiaomi is the obvious local share-gainer, and Samsung, which leads global foldable volume, benefits at the margin.

1810.HK

Buy Xiaomi — WSJ names local foldable makers as the demand winners post-announcement, and Xiaomi is the listed purest expression of that shift.

AAPL

Watch Apple — Rival demand rising specifically after the Duo announcement is a negative China tell, and at 34.8x forward with the stock 4% below its 52-week high there is no room for it.

$333.0 +1.10%

PE exits

FT reports Sycamore is close to a $9bn sale of Boots to the billionaire Weston family — one of the larger UK carve-outs this year. A clean exit at a firm price is the read on whether buyout funds can still monetise holdings at all. Public market proxies say they cannot: Blackstone is down 29.4% YTD and 34% below its 52-week high, KKR down 29.2% and 37% below. At 15.0x and 12.3x forward earnings, both price a realisation drought that one Boots deal does not end.

BX

Buy Blackstone — A $9bn Boots exit is evidence realisations are still clearing, and BX at 15.0x forward, 34% below its 52-week high, prices the opposite.

$112.1 -1.68%
KKR

Buy KKR — Same read-through on whether exits fund the next deployment cycle, with KKR 37% below its 52-week high at 12.3x forward.

$91.30 -2.02%

UK bank litigation

FT reports shipping executive Philip Adkins is suing Coutts, NatWest's private bank, alleging it kept a dossier of inaccurate information that triggered a US investigation. That is a step beyond the usual account-closure dispute and keeps the debanking narrative alive into next year. NatWest fell 2.5% last session and sits 8% below its 52-week high; Lloyds dropped 1.9% in the same session. UK banks remain cheap — Lloyds on 1.47x book, NatWest on 1.38x — so this is headline risk, not capital risk.

LLOY.L

Hold Lloyds — A widening debanking narrative raises compliance costs across UK retail banks, but Lloyds at 8.6x forward and 1.47x book has that overhang largely priced.

$104.8 -1.92%
NWG.L

Sell NatWest — Coutts is NatWest's private bank, so a repeat debanking suit is direct parent-level legal and headline risk with the stock already 8% below its 52-week high.

$671.2 -2.50%

Most original take

Alex Janin · WSJ Business · 1 Oct 2026

The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind

WSJ's Alex Janin argues the next obesity-drug winners will not be decided by how much weight patients lose but by what kind — muscle preserved versus fat lost. That moves the competitive axis off raw efficacy, where Novo has been ceding ground to Lilly, and onto formulation quality. For Amgen, whose MariTide uses a different mechanism, it is the cleanest route to differentiation. It is a framing piece with no trial data attached, but the framing is where the next three years of R&D dollars get allocated.

Read original ↗

Our view

Today's coverage has one organising tension: is the yield peak in? FT ran an optimist's guide to bonds and, the same morning, a column listing four positives from higher yields — a paper hedging its own house view. MarketWatch says retail is aggressively buying fixed-income ETFs at multi-decade yields after a harrowing Q3 for Treasurys. The tape says the crowd is early. TLT closed at its 52-week low, 16% below its high and touching the bottom of the range, while TBT, the double-short, sits 1% off its 52-week high at +21.7% YTD. Nothing in the last week looks like a peak.

Then Bloomberg lands the biggest quarterly jump in global crop prices since Russia invaded Ukraine, driven by Black Sea tension and weather, and frames it explicitly as a central-bank problem. Same day, Pandora's CEO tells Bloomberg US demand has stabilised at a low level on inflation and gas prices. If food inflation is re-accelerating, the bond bulls are buying the wrong part of the cycle — and XRT, down 4.4% YTD and only 6% above its 52-week low, is not going to rescue them. The crop funds themselves have already rolled over on the week, with WEAT -3.9% and MOS -8.6%, which is either the market calling the spike transitory or the cleanest entry in months.

The case against us is positioning, not fundamentals. TLT at exactly its 52-week low with retail buying hand over fist is maximum pain — and maximum squeeze. Add BofA's argument that the 'AI put', not yields, is what actually holds this market up, and you get QQQ parked 1% below its 52-week high with zero cushion beneath it. A soft CPI print plus a dovish Fed turn forces a violent unwind of the short-duration crowd and drags the AI complex along for the ride. We want the front end to rally first; if 2-year yields do not come in, the bond bull case is a value trap dressed as a contrarian trade.

What is missing is emerging markets. Laos is testing frontier access with a second dollar bond, potentially triple-C rated, less than a year after raising $300m in its first sale since 2019 — and nobody is covering the gap between EMB pinned at its 52-week low and EEM up 18.8% YTD. That EM credit-versus-equity spread is the most under-reported number of the day. The cleanest expression of today's split brain is not a single ticker: with AI capex and duration pulling in opposite directions, it is long dispersion — active over passive into the next two weeks.

Yesterday's signals, today

From the New York Edition on 30 Sept 2026 — 3/4 signals moved in the predicted direction.

Today's scan: 242 articles considered · 18 surfaced · across 14 publishers

Generated Thu 1 Oct 2026 8:05am New York · 35,505 views

Bloomberg Markets · CNBC Investing · CNBC Markets · CoinDesk · FT Alphaville · FT Companies · FT Lex · FT Markets · MarketWatch Top · Nikkei Asia · SCMP Business · The Information · WSJ Business · WSJ Markets

Next edition: London Edition tomorrow at 07:30 London.

Methodology
Share this edition